# A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

> **NCT06547840** · PHASE1 · RECRUITING · sponsor: **Epsilogen Ltd** · enrollment: 45 (estimated)

## Conditions studied

- Advanced Ovarian Cancer
- Platinum-resistant Ovarian Cancer
- Triple Negative Breast Cancer (TNBC)
- Triple -Negative Breast Cancer
- Endometrial Cancer
- Advanced Endometrial Cancer

## Interventions

- **DRUG:** MOv18 IgE

## Key facts

- **NCT ID:** NCT06547840
- **Lead sponsor:** Epsilogen Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-03
- **Primary completion:** 2026-07
- **Final completion:** 2027-03
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06547840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06547840, "A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06547840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*